Background: Pulmonary artery denervation (PADN) has been shown to improve hemodynamics of pulmonary arterial hypertension (PAH) in a series of patients. Additionally, benefits of targeted medical therapy for patients with combined pre-and post-capillary pulmonary hypertension (CpcPH) secondary to left sided heart failure are unknown. Objectives: We sought to assess the benefits of PADN among CpcPH patients in a prospective, randomized sham-controlled trial. Methods: N inety-eight CpcPH patients, defined as mean pulmonary arterial pressure ≥25 mmHg, pulmonary capillary wedge pressure >15 mmHg, and pulmonary vascular resistance (PVR] > 3.0 Woods Units, were randomly assigned to PADN or sildenafil plus sham PADN. Standard medical therapy for heart failure was administered to all patients in both groups. The primary endpoint was the increase in the 6-minute walk distance (6MWD) at the 6-month follow-up. The secondary endpoint was change in PVR. Clinical worsening was assessed in a post-hoc analysis. The main safety endpoint was occurrence of pulmonary embolism. Results: At 6-months, the mean increases in the 6MWD were 83 m in the PADN group and 15 m in the sildenafil group (least square mean difference 66 m, 95% confidence interval 38.2 to 98.8; p < 0.001). PADN treatment was associated with a significantly lower PVR than in the sildenafil group ( 4.2 ± 1.5 vs. 6.1 ± 2.9 Wood Units, p = 0.001). Clinical worsening was less frequent in the PADN group compared to the sildenafil group (16.7% vs. 40%, p = 0.014). At the end of the study, there were 7 all-cause deaths and 2 cases of pulmonary embolism. Conclusions: PADN is associated with significant improvements in hemodynamic and clinical outcomes in patients with CpcPH. Further studies are warranted to define its precise role in the treatment of this patient population.
PAC=pulmonary artery compliance PCWP=pulmonary capillary wedge pressure CO=cardiac output mPAP=mean pulmonary arterial pressure LVEF=left ventricular ejection fraction
INTRODUCTION
In patients with heart failure (HF) the backward transmission of increased left ventricular filling pressure results in elevated pulmonary venous pressure, a status known as passive or isolated post-capillary (Ipc) pulmonary hypertension (PH), without an elevation of pulmonary vascular resistance (PVR) or diastolic pressure gradient (DPG) (2-4). Fayyaz et al (5) reported that PH is associated with global pulmonary vascular remodeling, leading to reactive or combined pre-capillary and post-capillary PH (CpcPH), which is defined as a DPG of ≥ 7 mmHg, or a PVR of >3 Wood units (WU), or both (3, 4) . Although the presence of PH is a hallmark of poor clinical outcomes in patients with HF (1, 6) , controversy exists regarding the routine treatment of CpcPH with drugs targeting pulmonary arterial hypertension (7, 8) .
Previous studies (9, 10) have indicated that a superimposed pulmonary arterial vasoconstrictor component is one of the major mechanisms that leads to the development of CpcPH, suggesting the potential of pulmonary artery denervation (PADN) to target the overactivation of the sympathetic nerves in patients with heart failure and pulmonary hypertension.
Our preliminary registry study showed the safety and feasibility of PADN for either pulmonary arterial hypertension or PH secondary to left sided heart failure (11) . However, PADN has not been tested in a randomized comparison with a medical treatment. Accordingly, the present study (PADN-5) was designed as a prospective, randomized, sham-controlled trial to investigate the efficacy of pulmonary artery denervation in patients with pre-and post-capillary pulmonary hypertension associated with left heart failure.
METHODS

Study design
PADN-5 trial is a 4-center, randomized, and sham-controlled clinical trial. The study organization, participating sites and investigators appear in the Supplementary Appendix. The protocol was designed by the steering committee and was approved by the ethics committee at each participating center. All patients provided written informed consent. The risks of undergoing a PADN or sham PADN procedure were described in detail to all patients. Patients were informed that they had the right to withdraw their consent at any time. Sponsors had no access to the trial data and no role in the design, conduct, or reporting of the results. Clinical events were adjudicated by an independent committee. Authors attest to the accuracy and completeness of the data and analysis.
Patient selection
Patients who were admitted to the hospital with the diagnosis of HF (recent onset of dyspnea and physical activity limitation) were eligible for enrollment. A diagnosis of HF was independently adjudicated by 2 general cardiologists based on the current guidelines (5) . All patients were screened via a preliminary echocardiographic examination after they were stable for at least 3 days since the initial treatment on admission. Patients who had a systolic pulmonary arterial pressure (PAP) ≥45 mmHg (Supplemental Figure 1) were referred for right heart catheterization 12-24 hours after ultrasound measurements.
Inclusion and exclusion criteria
Eligible patients were randomly assigned in a 1:1 ratio to PADN or sildenafil plus sham PADN groups using a central interactive web-based computerized system. Patients were included if they were older than 18 years, had a mean PAP (mPAP) ≥25 mmHg, a pulmonary capillary wedge pressure (PCWP) >15 mmHg and a PVR >3.0 WU, volunteered for all followup assessments, and had not received any medications targeting PAH in the 3 months prior to admission. By contrast, patients were excluded if they had WHO-defined PAH groups I, III, IV and V; severe renal dysfunction (Ccr <30 mL/min); a blood platelet count <100,000/L; an expected lifespan <12 months based on DEALE method (12); systematic inflammation; malignancy, tricuspid or pulmonary valvular stenosis; or were allergic to any of the studied drugs or various metals. Women who were pregnant were also excluded.
Medication plan
Standard anti-HF medicines, including calcium channel blockers, β-adrenergic receptor blockers, digoxin, diuretics, angiotensin converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs), were administered. The dosage of anti-HF medications could be titrated if patients showed deterioration in any HF symptoms (1) (2) (3) (4) (5) (6) . A combination of diuretics Sildenafil, initially given at 20 mg 3 times daily, was the only primarily prescribed target drug in the Sildenafil group. Patients were titrated to 40 mg 3 times daily after 1 week. A dose reduction was allowed if patients were intolerable to titration. The selection and dosage of other target drugs were left at the discretion of the referring physician. This part of the study was not blinded (i.e. patients in the sham PADN group were given open-label sildenafil).
Echocardiographic measurements
Transthoracic echocardiography (Vivid 7, General Electric Co., Easton Turnpike, CT) was performed by 2 registered cardiac sonographers based on a standard protocol (9, 11) and read/measured by an expert echocardiographer from the Core Lab (Dr. Jing ping Sun from the Chinese University of Hong Kong) who was unaware of the study design and treatment allocation. The following parameters were measured: right ventricular systolic pressure, systolic PAP, right atrial pressure, the tricuspid excursion index, wall thickness, chamber dimension, the left ventricular ejection fraction (LVEF), mitral inflow velocity, septal annulus relaxation velocity (E'), the E/E' ratio, and tricuspid annular plane systolic excursion (TAPSE).
Hemodynamic measurements via right-side heart catheterization
Hemodynamic measurements were performed before and immediately after the PADN procedure using a 7. 
Assessment of N-terminal brain natriuretic peptide levels.
Blood samples (taken in the supine position) were obtained in the morning to measure the levels of N-terminal-pro brain natriuretic peptide (NT-proBNP) before and 6 months after randomization.
PADN procedure
The details of the device and the PADN procedure have been previously described (11) .
Briefly, PADN was performed only in the peri-conjunctional area between the distal main trunk and the ostial left branch. The following ablation parameters were programmed at each point:
temperature ≥45°C, energy ≤20 W, and time 120 seconds. The hemodynamic parameters were monitored and recorded continuously throughout the procedure. After the procedure, oral warfarin was prescribed for 1 month and adjusted to an international normalized ratio of 1.5 to 2.5 for patients with atrial fibrillation. Aspirin (100 mg per day) and clopidogrel (75 mg per day)
were prescribed for 1 month for patients with sinus rhythms or for patients with atrial fibrillation with contraindications for warfarin. For a sham PADN procedure in the Sildenafil group: the PADN catheter was positioned at the target sites and connected to a generator (as in the actual PADN procedure), but ablation was not performed. To simulate the true PADN procedure, discussions among the operator, technician, and nurses as well as beep sounds from the generator were recorded on a cell phone from a previous PADN procedure. This recording was played during the sham procedure, leading the patient to believe that a PADN procedure was being performed.
Assessment of functional capacity
Functional capacity was determined before, 1 week, 1 month, 3 months, and 6 months after treatment using the standard 6MWD test according to the guidelines of the American Thoracic Society (ATS) protocol. Patients avoided heavy meals 2 hours before testing and were also instructed to avoid caffeine, alcohol, tea, and intense physical exercise within the previous 24 hours. Before each test, patients walked as far as possible for 6 minutes without speaking;
rests were allowed, but the patients were told to resume walking as soon as they were able.
During the test, patients were given feedback at the end of every minute with encouragement.
Dyspnea was assessed using the Borg scale at peak exercise during 6MWD test. The 6MWD measurement and the WHO classification of dyspnea were recorded by a physician who was unaware of the treatment allocation.
Follow-up
Patients were contacted every month by telephone after hospital discharge during the 6-month follow-up period. An office visit at a participating center was scheduled for any patient who was suspected of having worsening symptoms. A repeat 6MWD measurement (within 2 weeks) was required for any patient who showed a reduction of >15% on the 6MWD.
Endpoints and definitions
The primary endpoint was the change in the 6MWD at 6-month follow-up evaluation.
The secondary endpoint was the change in PVR (measured using pulmonary hemodynamics during RHC) The safety endpoint was the occurrence of pulmonary embolism (PE), defined as 
Statistical analysis
We hypothesized that at 6 months, the increase of 6MWD would be higher among patients in the PADN group than among patients in the Sildenafil group. We anticipated a standard deviation and mean value of the difference for the 6MWD increase at 85 m and 60 m according to our previous results (9) . We estimated that a sample size of 41 patients in each group would provide 80% power with a 2-tailed alpha of 0.025. To account for a possible 20%
of patients lost to follow-up, 100 patients (50 in each group) were planned for enrollment. All analyses were performed on an intention-to-treat basis. Data on patients who were lost to followup were censored at the date of the last contact with the patient. The categorical variables were reported as counts and percentage and compared using the chi-square test or Fisher's exact test.
The continuous variables were expressed as means ± SD or median (interquartile [IQR] or range)
and compared using Student's t test or the Wilcoxon rank-sum score (for example, for comparison of 6MWD between groups or between baseline and 6 months follow-up) where appropriate. The change of the 6MWD in individual patients was illustrated using a scatterplot.
The corresponding hazard ratio (HR) and 95% confidence interval (CI) for a decrease of 1 SD in the 6MWD for the prediction of clinical worsening and all-cause death were calculated using a Cox Proportional hazard model. Time-to-first event curves were generated by Kaplan-Meier analysis and compared using the log-rank test. The Cox Proportional hazard model was also used to calculate the difference in the occurrence of time-to-clinical event between 2 planned groups, with reports of HR and 95% CI. Additional post-hoc analyses included the receiver operator characteristic (ROC) curve and the correlation between PVR and PAC or between the absolute increment of the 6MWD and PAC using a Regression Variable Plot and curve estimation (inverse model). Prespecified subgroup analyses included: difference in 6MWD between EFpreserved HF (HFpEF, defined as LVEF ≥50%) vs. EF-reduced HF (HFrEF, defined as LVEF <50%), time-to-event stratified by cut-off values of the 6MWD at baseline or at 6-month followup. Two-tailed P values of less than 0.05 were considered to indicate statistical significance. All analyses were performed using SPSS version 24.0 (SPSS Institute Inc., Chicago, IL, USA).
RESULTS
Patient population
Among 865 screened patients, 387 patients with HF had a systolic PAP ≥45 mmHg measured by echocardiography. Among them, 112 (28.9%) patients met all the inclusion and exclusion criteria; however, 2 died soon after echocardiographic screening, and 10 did not consent to participate. Of the remaining 100 patients, 98 were then randomly assigned to the PADN group (n = 48) or the Sildenafil (plus sham PADN) group (n = 50) (Supplemental Figure   1 ). Two patients were excluded because of erroneous repeat randomization by the study nurses.
Baseline characteristics
Baseline clinical, echocardiographic, and hemodynamic characteristics were similar between the 2 groups ( (Table 2) .
Primary endpoint
The baseline 6MWD was comparable between the 2 groups (Figure 1 ). In the PADN group, the mean increment of the 6MWD at the 6-month follow-up was 83 m (21. (Table 4) .
Secondary Endpoint
At 6 months, PADN treatment was associated with a significantly lower PVR than in the sildenafil group (4.2 ± 1.5 vs. 6.1 ± 2.9 Wood Units, p = 0.001). The average reduction of PVR from baseline to 6-months RHC was 29.8% in the PADN group and 3.4% in the Sildenafil group (HR 4.73, 95% CI 2.05-10.89, p < 0.001, Table 2 ), which was consistent with the increase of cardiac output and PAC.
Post-hoc analysis
At the 6-month follow-up, clinical worsening was reported in 28 patients (Table 3 and Figure 2C ), primarily driven by the protocol defined worsening of HF (36.0% vs. 14.6%, HR 2.743, 95% CI 1.145-6.571, p = 0.024, Figure 2D ). The PADN procedure was associated with significant improvements in all hemodynamic parameters (Table 2) , except for right atrial pressure which tended to be lower, but there was no significant difference. PAC
was significantly improved at 6 months after PADN, in parallel with the absolute increase in the 6MWD (Supplemental Figures 3B and 3E ). However, PVR was unchanged after 6 months in the Sildenafil group (Supplemental Figure 3C and 3F). These results were in line with the lower requirement for diuretic titration, the reduction of NT-proBNP, Borg index, and improvement of cardiac function (Table 3) . Of the 48 patients in the PADN group, 4 (8.3%) were non-responders, defined as a reduction of mPAP or sPAP <10% post-PADN (9), and 3 patients showed a post-PADN PCWP higher than the baseline value (but no worsening of symptoms). For these three patients, repeat RHC was performed 1 week after PADN, and the temporary increment of PCWP decreased thereafter. At 6 months, 6MWD measurement was a statistically significant predictor of clinical worsening or all-cause death (Supplemental Figure 4) .
Safety endpoint
At the 6-month follow-up, 2 fatal pulmonary embolisms were reported, with one at 72 days after randomization in the PADN group and the other at 36 days in the sildenafil group.
There were 7 deaths: 2 in the PADN group (one died of pump failure at 6 days, the other died suddenly at 29 days) and 5 in the Sildenafil group (one died suddenly at 17 days, and the remaining 4 died of pump failure at 17, 93, 100, and 154 days).
DISCUSSION
The present randomized sham-controlled study is the first to report the safety and efficacy of PADN for patients with CpcPH. We found that after a 6-month follow-up, PADN resulted in a significant increase in the 6MWD, consistent with the significant improvements in PVR, other hemodynamic parameters and cardiac function. Post-hoc analysis demonstrated significantly less frequent clinical worsening with PADN compared to sildenafil therapy. A decrease of 1-SD in the 6MWD strongly predicted the occurrence of clinical worsening.
The development of PH is a common complication related to left-sided HF (1-3, 5).
Previous clinical studies did not confirm the effectiveness of medications targeting pulmonary arterial hypertension for patients with HF and PH (1, 3, 5), although meta-analysis studies reported an overall benefit of sildenafil for IpcPH patients (8, 16) . This controversy regarding the beneficial effect of sildenafil for CpcPH underscores the importance of fully understanding the neurohumoral mechanisms in these patients (17) .
Neurohumoral over-activation in HF with PH is clinically demonstrated by increased circulating catecholamine levels and impaired heart rate variability (6, 7, 18) , which may indicate the potential of using local denervation for patients with CpcPH. In an experimental study, we further found that both the localization of PA nerve trunk ((at the left lateral wall of main PA) and a shorter distance between nerve trunk and PA intimal surface (19) anatomically favor the performance of PADN at this specific location. Furthermore, PADN was tested in a single center registry of patients with idiopathic pulmonary arterial hypertension and PH secondary to left-sided HF, demonstrating beneficial effects on hemodynamic parameters and exercise capacity (11, 20) . In the present randomized study, PADN treatment (plus standard anti-HF medications)
was associated with a significant increase in 6MWD at the 6-month follow-up, which was in parallel to the improvement in pulmonary hemodynamics and cardiac functions, compared with the effects of sildenafil plus standard medications, which further confirmed our previous reports (11, 20) . We attempted to minimize or eliminate the placebo effect by performing a sham PADN procedure on patients in the sildenafil group. Blinding may not have been complete due to the open administration of sildenafil in only one of the randomized groups.
The 6MWD was selected as the primary endpoint in previous studies of patients with pulmonary arterial hypertension, and a >15% reduction in the 6MWD is a criterion for clinical event (6, 10 ). An 83 m increase in 6MWD achieved by PADN treatment from the present study was similar to the 90 m increase in our previous reports (11, 20) . Moreover, McCabe et al (24) reported that the baseline 6MWD predicted the 30-day re-hospitalization rate among patients We further found that a significant reduction of clinical worsening in the PADN group, mainly driven by the decrease in the rate of worsening of HF in the PADN group. This is different to the significant reduction of re-hospitalization in previous studies (16, 17) , which may be explained by the differences in the definitions of worsening of HF and re-hospitalization between studies. This unexpected clinical benefit from the PADN procedure is an indication for our next clinical trial. However, the mechanisms underlying the interplay between pulmonary arterial hemodynamics and exercise capacity in HF patients were complicated and not fully understood in CpcPH patients (2) (3) (4) (5) . In this study, the improvements in the PAC-PVR and PAC-6MWD relationships achieved by the PADN procedure suggested the sustained recovery of stiffer pulmonary arterial structure (25) rather than a change in remodeling status affecting small arterioles. Notably, the reduction in PCWP achieved by PADN dispelled our original concerns that PCWP would undergo a deleterious change because there is a large amount of blood return following mPAP reduction and cardiac output increases (hyperkinetic status) (3-7) after PADN.
In fact, the decrease in PCWP in this study may well explain the significant reduction in both left atrial and left ventricular diameters, which is consistent with the improvements in 6MWD, left ventricular systolic and diastolic functions when compared with medication treatment; a finding which implied the potential role of PADN for left ventricular remodeling. This improvement in left ventricular function is unlikely to be due to the right-left interaction, because right ventricular function was marginally altered. Interestingly, the improvements in the hemodynamic parameters and right ventricular function after the PADN procedure were not followed by a statistically significant education in right atrial dimension and RAP. This is not clearly understood. It could be explained by the fact that 6 months of follow-up was too short a time to record the improvement in right atrial dimension/pressure in such severe cases of patients with
CpcPH and indicates the importance of long-term follow-up.
Limitations
The present study has several limitations. First, we selected to use sildenafil plus standard medical therapy and sham PADN in the control group, even though neither sildenafil nor other PAH therapies, are recommended in patients with CpcPH according to international guidelines.
We based this decision on a meta-analysis demonstrating beneficial effects of sildenafil in PAH patients, but it should be clear that our data did not provide support for the use of these agents in
CpcPH. Second, the use of sildenafil without a comparable placebo in the PADN group may have affected the blinding of patients and treating physicians to the treatment allocation. Third, the 6MWD, but not the clinical endpoint, was the primary endpoint in this study. There is a wellknown learning effect and 6MWD measurements may be different from day to day (20, 21) . As result, the interpretation of our results should be made cautiously. Fourth, patients were screened only after being treated medically for only 3 days and adequate diuresis was not objectively Xu for the data monitoring and collection performed throughout the study. We appreciate Dr.
Baoxiang Duan (Director of the Event Committee) for his valuable work in assessing the clinical events. We thank Dr. Ori-Ben Yehuda for hemodynamic measurement instruction before this study.
PERSPECTIVES WHAT IS KNOWN?
Heart failure (HF) is a leading cause of mortality. Combined pre-and post-capillary (Cpc) PH in HF patients can be severe and is a marker of poor clinical outcomes. Optimal therapies in patients with CpcPH are not clear.
WHAT IS NEW?
Pulmonary artery denervation (PADN) not been studied for CpcPH in a randomized shamcontrolled design.
WHAT IS NEXT?
In this multicenter, randomized, sham-controlled study, PADN plus standard medical therapy led to a significant improvement in the 6MWD and PVR. It was also associated with a significantly lower rate of clinical worsening, compared to patients treated with sildenafil and standard medical therapy. eGFR, estimated glomerular filtration rate; HF, heart failure; EFpHF, ejection fraction preserved heart failure; PH, pulmonary hypertension; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker 
